Naltrexone augmentation of neuroleptics in schizophrenia

Journal of Clinical Psychopharmacology

Volumn 18, Issue 3, 1998, Pages 248-251

  Sernyak, Michael J ^a,f   Glazer, William M ^d   Heninger, George R ^b   Charney, Dennis S ^a,b   Woods, Scott W ^c   Petrakis, Ismene L ^c   Krystal, John H ^a   Price, Lawrence H ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Yale University School of Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BROWN UNIVERSITY   (United States)

^f VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPHENAZINE; HALOPERIDOL; NALTREXONE; NEUROLEPTIC AGENT; OPIATE ANTAGONIST; TRIFLUOPERAZINE;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUPHENAZINE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; SCHIZOPHRENIA;

EID: 0031860344     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199806000-00011     Document Type: Article

References (27)

1. Mueser KT, Dysken MW. Narcotic antagonists in schizophrenia: a methodological review. Schizophr Bull 1983;9:213-25.
2. Nemeroff CB, Berger PA, Bissette G. Peptides in schizophrenia. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven, 1987:727-43.
3. Terenius L, Wahlstrom A, Lindstrom L. Increased CSF levels of endorphins in chronic psychosis. Neurosci Lett 1976;3:157-62.
4. Iadarola MJ, Ofri D, Kleinman JE. Enkephalin, dynorphin, and substance P in postmortem substantia nigra from normals and schizophrenic patients. Life Sci 1991;48:1919-30.
5. Gold MS, Donabedian RK, Dillard M, Slobetz FW, Riordan CE, Kleber HD. Antipsychotic effect of opiate agonists. Lancet 1978;2: 398-9.
6. Judd LL, Janowsky DS, Segal DS, Parker DC, Huey LY. Behavioral effects of methadone in schizophrenic patients. Am J Psychiatry 1991;138:243-5.
7. Pickar D, Davis GC, Schulz SC, Extein I, Wagner R, Naber D, Gold PW, van Kammen DP, Goodwin FK, Wyatt RJ, Li CH, Bunney WE. Behavioral and biological effects of acute β-endorphin injection in schizophrenic and depressed patients. Am J Psychiatry 1981; 138:160-6.
8. Gunne LM, Lindstrom L, Terenius L. Naloxone-induced reversal of schizophrenic hallucinations. J Neural Transm 1970;40: 3-19.
9. Naber D, Munch U, Wissmann J, Grosse R, Ritt R, Welter D. Naloxone treatment for five days ineffective in schizophrenia. Acta Psychiatr Scand 1983;67:265-71.
10. Pickar D, Bunney WE, Douillet P, Sethi BB, Sharma M, Vartanian ME, Lideman RP, Naber D, Leibl K, Yamashita I, Koyama T, Verhoven WMA, Vartanian F, Morozov PV, Khac TN. Repeated naloxone administration in schizophrenia: a phase II World Health Organization study. Biol Psychiatry 1989;25:440-8.
11. Mielke DH, Gallant DM. An oral opiate antagonist in chronic schizophrenia: a pilot study. Am J Psychiatry 1977;134:1430-1.
12. Gitlin MJ, Rosenblatt M. Possible withdrawal from endogenous opiates in schizophrenics. Am J Psychiatry 1978;35:377-8.
13. Gitlin MJ, Gerner RH, Rosenblatt M. Assessment of naltrexone in the treatment of schizophrenia. Psychopharmacology 1981;74: 51-3.
14. Marchesi GF, Santone G, Cotani P, Troiani G. Naltrexone integrated neuroleptic treatment in schizophrenia. Biol Psychiatry 1991;29[suppl]:536.
15. Marchesi GF, Santone G, Cotani P, Giordano A, Chelli F. Naltrexone in chronic negative schizophrenia. Clin Neuropharmacol 1992;15:56A-57A.
16. Rapaport MH, Wolkowitz O, Kelsoe JR, Pato C, Konicki PE, Pickar D. Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients. Neuropsychopharmacology 1993;9:111-5.
17. Davis JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res 1974;11:65-9.
18. Overall JE. Psychological measurements in psychopharmacology. In: Pichot P, ed. Modern problems in pharmacopsychiatry. Basel: Karger, 1974:67-78.
19. Guy W. ECDEU assessment manual for psychopharmacology (US Department of Health, Education, and Welfare Publication 76-338). Washington: Alcohol, Drug Abuse, and Mental Health Administration, 1976.
20. Webster DD. Clinical analysis of the disability in Parkinson's disease. Mod Treat 1968;5:257-82.
21. Hedlund JL, Vieweg BW. The Brief Psychiatric Rating Scale (BPRS): a comprehensive review. J Operational Psychiatry 1980; 11:48-64.
22. Thiemann S, Csernansky JG, Berger PA. Rating scale in research: the case of negative symptoms. Psychiatry Res 1987;20:47-55.
23. Kane J, Hongifeld G, Singer J, Meltzer HY. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
24. Seibyl JP, Krystal JH, Brenner L, Erdos J, Johnson R, Karper L, Charney DS. Mazindol augmentation of neuroleptic in negative symptom schizophrenia: preliminary placebo-controlled double-blind, and open-label extension studies. J Clin Psychopharmacol, in press.
25. Drake RE, Osher FC, Wallace MA. Alcohol use and abuse in schizophrenia: a prospective community study. J Nerv Ment Dis 1980; 177:408-14.
26. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 1992;49:881-7.
27. Volpicelli JR, Alterman AI, Hayashida M, O'Brien C. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876-80.